$CVSI
CV Sciences, Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024059926 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $3.954M $4.002M $4.148M
YoY Change -0.3% -3.52% -6.72%
Cost Of Revenue $2.094M $2.149M $2.366M
YoY Change -6.85% -9.17% -28.11%
Gross Profit $1.860M $1.853M $1.782M
YoY Change 8.27% 3.98% 54.15%
Gross Profit Margin 47.04% 46.3% 42.96%
Selling, General & Admin $2.415M $2.437M $2.156M
YoY Change -12.44% 13.03% -15.45%
% of Gross Profit 129.84% 131.52% 120.99%
Research & Development $28.00K $36.00K $35.00K
YoY Change -22.22% 2.86% -71.07%
% of Gross Profit 1.51% 1.94% 1.96%
Depreciation & Amortization $76.00K $63.00K $59.00K
YoY Change 28.81% 6.78% -88.59%
% of Gross Profit 4.09% 3.4% 3.31%
Operating Expenses $2.443M $2.473M $2.191M
YoY Change -12.56% 12.87% -17.97%
Operating Profit -$583.0K -$620.0K $5.762M
YoY Change -45.82% -110.76% -480.33%
Interest Expense -$56.00K
YoY Change -92.02%
% of Operating Profit -0.97%
Other Income/Expense, Net -$1.000K -$2.000K -$56.00K
YoY Change -99.52% -96.43%
Pretax Income -$584.0K -$622.0K $5.706M
YoY Change -54.55% -110.9% -357.37%
Income Tax $0.00 $6.000K $0.00
% Of Pretax Income 0.0%
Net Earnings -$584.0K -$628.0K $5.706M
YoY Change -54.66% -111.01% -357.37%
Net Earnings / Revenue -14.77% -15.69% 137.56%
Basic Earnings Per Share $0.00 $0.00 $0.04
Diluted Earnings Per Share $0.00 $0.00 $0.04
COMMON SHARES
Basic Shares Outstanding 163.2M 163.2M 152.1M shares
Diluted Shares Outstanding 172.4M 163.1M 152.1M shares

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $477.0K $662.0K $714.0K
YoY Change -71.78% -7.28% -70.73%
Cash & Equivalents $477.0K $662.0K $714.0K
Short-Term Investments
Other Short-Term Assets $410.0K $426.0K $2.103M
YoY Change -0.24% -79.74% -39.01%
Inventory $5.206M $5.756M $6.526M
Prepaid Expenses
Receivables $639.0K $507.0K $657.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $6.732M $7.351M $10.00M
YoY Change -21.24% -26.49% -33.57%
LONG-TERM ASSETS
Property, Plant & Equipment $666.0K $319.0K $516.0K
YoY Change 45.73% -38.18% -53.13%
Goodwill $729.0K $340.0K
YoY Change
Intangibles $106.0K $73.00K $251.0K
YoY Change -57.77% -70.92% -83.1%
Long-Term Investments
YoY Change
Other Assets $202.0K $244.0K $452.0K
YoY Change -49.63% -46.02% -27.8%
Total Long-Term Assets $2.154M $1.115M $1.468M
YoY Change 61.83% -24.05% -54.3%
TOTAL ASSETS
Total Short-Term Assets $6.732M $7.351M $10.00M
Total Long-Term Assets $2.154M $1.115M $1.468M
Total Assets $8.886M $8.466M $11.47M
YoY Change -10.05% -26.18% -37.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.307M $2.460M $2.441M
YoY Change 6.76% 0.78% -9.76%
Accrued Expenses $3.461M $3.248M $3.241M
YoY Change -2.15% 0.22% -68.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $29.00K $117.0K $451.0K
YoY Change 3.57% -74.06% 153.37%
Total Short-Term Liabilities $6.031M $5.959M $6.253M
YoY Change 3.11% -4.7% -55.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $95.00K $103.0K $157.0K
YoY Change -24.0% -34.39%
Total Long-Term Liabilities $95.00K $103.0K $157.0K
YoY Change -24.0% -34.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.031M $5.959M $6.253M
Total Long-Term Liabilities $95.00K $103.0K $157.0K
Total Liabilities $6.378M $6.104M $6.421M
YoY Change 6.57% -4.94% -54.96%
SHAREHOLDERS EQUITY
Retained Earnings -$85.80M -$85.20M -$82.00M
YoY Change 3.0% 3.9% 0.37%
Common Stock $18.00K $16.00K $15.00K
YoY Change 20.0% 6.67% 25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.508M $2.362M $5.047M
YoY Change
Total Liabilities & Shareholders Equity $8.886M $8.466M $11.47M
YoY Change -10.05% -26.18% -37.22%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$584.0K -$628.0K $5.706M
YoY Change -54.66% -111.01% -357.37%
Depreciation, Depletion And Amortization $76.00K $63.00K $59.00K
YoY Change 28.81% 6.78% -88.59%
Cash From Operating Activities -$57.00K -$500.0K $975.0K
YoY Change -104.04% -151.28% -343.75%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$40.00K
YoY Change
Cash From Investing Activities -$40.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -87.00K -136.0K -$872.0K
YoY Change -80.0% -84.4% -160.43%
NET CHANGE
Cash From Operating Activities -57.00K -500.0K $975.0K
Cash From Investing Activities -40.00K
Cash From Financing Activities -87.00K -136.0K -$872.0K
Net Change In Cash -184.0K -655.0K $103.0K
YoY Change -118.85% -735.92% -90.32%
FREE CASH FLOW
Cash From Operating Activities -$57.00K -$500.0K $975.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001510964
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2023Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#ProductMember
CY2024Q1 us-gaap Indefinite Lived Intangible Assets Foreign Currency Translation Gain Loss
IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
000-54677
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
CV Sciences, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
80-0944970
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
9530 Padgett Street, Suite 107
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92126
CY2024Q1 dei City Area Code
CityAreaCode
866
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
290-2157
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
163228469
CY2024Q1 us-gaap Cash
Cash
662000
CY2023Q4 us-gaap Cash
Cash
1317000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
507000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
431000
CY2024Q1 us-gaap Inventory Net
InventoryNet
5756000
CY2023Q4 us-gaap Inventory Net
InventoryNet
5655000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
426000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
535000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
7351000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
7938000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
319000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
379000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
139000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
167000
CY2024Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
73000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
78000
CY2024Q1 us-gaap Goodwill
Goodwill
340000
CY2023Q4 us-gaap Goodwill
Goodwill
342000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
244000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
296000
CY2024Q1 us-gaap Assets
Assets
8466000
CY2023Q4 us-gaap Assets
Assets
9200000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2460000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2309000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3248000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3422000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
134000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
130000
CY2024Q1 cvsi Long Term Debt Excluding Convertible Debt Current Maturities
LongTermDebtExcludingConvertibleDebtCurrentMaturities
117000
CY2023Q4 cvsi Long Term Debt Excluding Convertible Debt Current Maturities
LongTermDebtExcludingConvertibleDebtCurrentMaturities
254000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
5959000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6115000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
58000
CY2024Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
19000
CY2023Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
19000
CY2024Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
103000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
105000
CY2024Q1 us-gaap Liabilities
Liabilities
6104000
CY2023Q4 us-gaap Liabilities
Liabilities
6297000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1000
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
790000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
790000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
163228000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
163228000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
161678000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
161678000
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
16000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
16000
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
87556000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
87464000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85215000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84587000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
10000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2362000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2903000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8466000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9200000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4002000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4148000
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
2149000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
2366000
CY2024Q1 us-gaap Gross Profit
GrossProfit
1853000
CY2023Q1 us-gaap Gross Profit
GrossProfit
1782000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2437000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2156000
CY2024Q1 cvsi Payroll Tax Expense Reversal
PayrollTaxExpenseReversal
0
CY2023Q1 cvsi Payroll Tax Expense Reversal
PayrollTaxExpenseReversal
-6171000
CY2024Q1 cvsi Operating Costs And Expenses Net
OperatingCostsAndExpensesNet
2473000
CY2023Q1 cvsi Operating Costs And Expenses Net
OperatingCostsAndExpensesNet
-3980000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-620000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
5762000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-56000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-622000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5706000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-628000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
5706000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
163075000
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
163075000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
152104000
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
152104000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-628000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
5706000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-633000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5706000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
2903000
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
62000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
30000
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-628000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2362000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-777000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
118000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
5706000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
5047000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-628000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
5706000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
63000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
59000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
30000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
118000
CY2024Q1 cvsi Debt Discount And Interest Expense
DebtDiscountAndInterestExpense
0
CY2023Q1 cvsi Debt Discount And Interest Expense
DebtDiscountAndInterestExpense
100000
CY2024Q1 cvsi Noncash Lease Expense
NoncashLeaseExpense
28000
CY2023Q1 cvsi Noncash Lease Expense
NoncashLeaseExpense
26000
CY2024Q1 cvsi Payroll Tax Expense Reversal
PayrollTaxExpenseReversal
0
CY2023Q1 cvsi Payroll Tax Expense Reversal
PayrollTaxExpenseReversal
-6171000
CY2024Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
108000
CY2023Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
59000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
70000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-102000
CY2024Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
102000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-37000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-109000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1087000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-56000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-148000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-518000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
975000
CY2024Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
50000
CY2023Q1 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
764000
CY2024Q1 us-gaap Repayments Of Unsecured Debt
RepaymentsOfUnsecuredDebt
86000
CY2023Q1 us-gaap Repayments Of Unsecured Debt
RepaymentsOfUnsecuredDebt
108000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-136000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-872000
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-655000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
103000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1317000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
611000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
662000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
714000
CY2024Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
4000
CY2023Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
3000
CY2024Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
6000
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0
CY2024Q1 cvsi Services Paid With Common Stock
ServicesPaidWithCommonStock
62000
CY2023Q1 cvsi Services Paid With Common Stock
ServicesPaidWithCommonStock
0
CY2024Q1 cvsi Liquidity Considerations Policy Policytextblock
LiquidityConsiderationsPolicyPolicytextblock
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Liquidity Considerations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> - U.S. GAAP requires management to assess a company's ability to continue as a going concern for a period of one year from the financial statement issuance date and to provide related note disclosure in certain circumstances. The accompanying financial statements and notes have been prepared assuming the Company will continue as a going concern. The Company generated negative cash flows from operations of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million for the three months ended March 31, 2024 and had an accumulated deficit of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">85.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million as of March 31, 2024. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operations, growth initiatives and to continue to make and implement strategic cost reductions, including reductions in employee headcount, vendor spending, and delaying expenses related to its drug development activities. The Company is positioning itself to raise additional funds through the capital markets, issuance of debt, and/or securing lines of credit.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company's financial operating results and accumulated deficit, amongst other factors, raise substantial doubt about the Company's ability to continue as a going concern. The Company will continue to pursue the actions outlined above, as well as work towards increasing revenue and operating cash flows to meet its future liquidity requirements. However, there can be no assurance that the Company will be successful in any capital-raising efforts that it may undertake, and the failure of the Company to raise additional capital could adversely affect its future operations and viability.</span></p>
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-500000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85200000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> - The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements and accompanying notes. Actual results may differ from these estimates. Significant estimates include the valuation of intangible assets, inputs for valuing equity awards, valuation of inventory and assumptions related to revenue recognition.</span></p>
CY2024Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
0
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4002000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4148000
CY2024Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
2864000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2892000
CY2024Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
1291000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1181000
CY2024Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1601000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1582000
CY2024Q1 us-gaap Inventory Gross
InventoryGross
5756000
CY2023Q4 us-gaap Inventory Gross
InventoryGross
5655000
CY2024Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
522000
CY2023Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
522000
CY2024Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1354000
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1388000
CY2024Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1372000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1512000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3248000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3422000
CY2023Q4 us-gaap Goodwill
Goodwill
342000
CY2024Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-2000
CY2024Q1 us-gaap Goodwill
Goodwill
340000
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2024Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2024Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
78000
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
78000
CY2024Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-5000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-1000
CY2023 us-gaap Indefinite Lived Intangible Assets Foreign Currency Translation Gain Loss
IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
1000
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
73000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
78000
CY2023Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
78000
CY2024Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4000
CY2024Q1 us-gaap Finite Lived Intangible Assets Foreign Currency Translation Gain Loss
FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
-1000
CY2024Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
73000
CY2024Q1 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
300000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
400000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
200000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
100000
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
28238
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
26174
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P14M
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.07
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
105000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
59000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
164000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
157000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
134000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
157000
CY2024Q1 cvsi Long Term Debt Excluding Convertible Debt Current Maturities
LongTermDebtExcludingConvertibleDebtCurrentMaturities
117000
CY2023Q4 cvsi Long Term Debt Excluding Convertible Debt Current Maturities
LongTermDebtExcludingConvertibleDebtCurrentMaturities
254000
CY2024Q1 cvsi Cares Act Term For Repayment Of Debt Instrument To Avoid Penalty
CARESActTermForRepaymentOfDebtInstrumentToAvoidPenalty
P90D
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10750000
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10750000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
200000
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
24435000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.32
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y4M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
0
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
11687000
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.42
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12748000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.24
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
6000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7059000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.39
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y1M6D
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
12748000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.24
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y10M24D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
6000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.32
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.038
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M7D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.04
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
30248000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
42231000
CY2024Q1 cvsi Net Operating Loss Tax Benefit Recognized
NetOperatingLossTaxBenefitRecognized
0
CY2023Q1 cvsi Net Operating Loss Tax Benefit Recognized
NetOperatingLossTaxBenefitRecognized
0
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-059926-index-headers.html Edgar Link pending
0000950170-24-059926-index.html Edgar Link pending
0000950170-24-059926.txt Edgar Link pending
0000950170-24-059926-xbrl.zip Edgar Link pending
cvsi-20240331.htm Edgar Link pending
cvsi-20240331.xsd Edgar Link pending
cvsi-ex2_1.htm Edgar Link pending
cvsi-ex31_1.htm Edgar Link pending
cvsi-ex31_2.htm Edgar Link pending
cvsi-ex32_1.htm Edgar Link pending
cvsi-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
cvsi-20240331_htm.xml Edgar Link completed
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending